First Clinical Trial of Specific IKACh Blocker Shows No Reduction in Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation: Pacemaker Assessment of BMS 914392 in Patients With Paroxysmal Atrial Fibrillation

Europace. 2016 Mar;18(3):340-6. doi: 10.1093/europace/euv263. Epub 2015 Oct 12.

Abstract

Aims: To assess the efficacy of BMS 914392 on atrial fibrillation (AF) burden reduction in 20 patients with pacemakers and paroxysmal atrial fibrillation (PAF). BMS 914392 is a potent, selective, oral inhibitor of the IKACh current and has been shown to suppress AF, whilst having no effect on the ventricular refractory period. This is the first efficacy study of BMS 914392 in patients with PAF.

Methods and results: The study was a four-way, crossover, double-blind design. A total of 20 patients with PAF and dual-chamber pacemakers were recruited. The pacemakers allowed beat-to-beat monitoring. Anti-arrhythmic drugs were withdrawn. Patients received low-dose (10 mg OD), medium-dose (10 mg TDS), and high-dose (20 mg TDS) BMS 914392 or placebo for 3 weeks before being crossed to the next phase. Patients underwent a washout period, four treatment phases and a final washout phase. Atrial fibrillation burden was downloaded from their pacemakers at the end of each study phase. BMS 914392 did not reduce AF burden when compared with placebo (10 mg OD P = 0.56, 10 mg TDS P = 0.22, 20 mg TDS P = 0.23). Heart rate and corrected QT (QTc) were not affected by BMS 914392. Adverse event (AE) rates did not differ from placebo in any of the treatment groups, with no serious AEs recorded.

Conclusion: BMS 914932 has not been shown to reduce AF burden in patients with PAF and pacemakers using beat-to-beat pacemaker monitoring throughout the study. BMS 914392 was well tolerated and did not affect QTc or reduce heart rate.

Trial registration: Clinicaltrials.gov: NCT01356914.

Keywords: AF burden; Anti-arrhythmic drugs; Atrial-specific antiarrhythmic drugs; IKACh current; Pacemaker monitoring; Paroxysmal atrial fibrillation.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Action Potentials
  • Aged
  • Anti-Arrhythmia Agents / adverse effects
  • Anti-Arrhythmia Agents / therapeutic use*
  • Atrial Fibrillation / diagnosis
  • Atrial Fibrillation / physiopathology
  • Atrial Fibrillation / therapy*
  • Cardiac Resynchronization Therapy Devices*
  • Cardiac Resynchronization Therapy*
  • Cross-Over Studies
  • Double-Blind Method
  • Electrocardiography
  • England
  • Female
  • G Protein-Coupled Inwardly-Rectifying Potassium Channels / antagonists & inhibitors*
  • G Protein-Coupled Inwardly-Rectifying Potassium Channels / metabolism
  • Heart Conduction System / drug effects*
  • Heart Conduction System / metabolism
  • Heart Conduction System / physiopathology
  • Heart Rate / drug effects*
  • Humans
  • Male
  • Potassium Channel Blockers / adverse effects
  • Potassium Channel Blockers / therapeutic use*
  • Pyrans / adverse effects
  • Pyrans / therapeutic use*
  • Quinolines / adverse effects
  • Quinolines / therapeutic use*
  • Time Factors
  • Treatment Outcome

Substances

  • Anti-Arrhythmia Agents
  • BMS 914392
  • G Protein-Coupled Inwardly-Rectifying Potassium Channels
  • Potassium Channel Blockers
  • Pyrans
  • Quinolines

Associated data

  • ClinicalTrials.gov/NCT01356914